On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Honebuto Outline Includes “Raise in Official Prices,” but Details Yet Unknown
May 27, 2025
-
COMMENTARY Next Wave of ALS Drugs Emerging as Novartis, Nipro Enter Development Fray
May 27, 2025
-
BUSINESS Sun Pharma Japan Eyes 10%-Plus CAGR as It Pivots to New Drug Biz
May 26, 2025
-
BUSINESS Novartis Keen to Ensure Stable Supply of Radioligand Therapies in Japan
May 26, 2025
-
ORGANIZATION FPMAJ Sets Out on New Lobbying Push with Astellas’ Yasukawa as New Chief
May 23, 2025
-
ORGANIZATION Takeda’s Miyabashira Elected as New JPMA President
May 23, 2025
-
BUSINESS Japan Pharma Market Grows 1% to Record 11.4 Trillion Yen in FY2024: IQVIA
May 23, 2025
-
BUSINESS MSD Chief Decries Japan’s Unpredictable Policy Flip, Frets Future Investment
May 22, 2025
-
BUSINESS Sanofi Japan Seeing Improved Customer Satisfaction with AI-Powered Sales Support Tool
May 21, 2025
-
REGULATORY Japan Approves Moderna RSV Vaccine, GSK’s ADC, and More
May 20, 2025
-
ORGANIZATION PhRMA Raps Japan’s Drug Price Controls as Non-Tariff Trade Barriers, Urges US Govt Action
May 19, 2025
-
BUSINESS Eisai Aims to Turn Leqembi to Black in FY2026 with EU Approval as Tailwind: CEO
May 16, 2025
-
REGULATORY Chuikyo Agrees to Vet Conditional Scheme for Regenerative Medicine as Elevidys Gets Approval
May 15, 2025
-
REGULATORY Eylea’s Price to Be Axed by 19.5%, Jardiance 12.1% in Market Expansion Rule
May 15, 2025
-
REGULATORY Wegovy, Leqvio, Phozevel Braced for Price Cuts after CEA
May 15, 2025
-
REGULATORY Chuikyo Plans Monthly Debates for CEA Reform in FY2026
May 15, 2025
-
REGULATORY Epkinly, Lunsumio to Face Price Cut of 2.7% under CEA Scheme
May 15, 2025
-
REGULATORY Japan’s Parliament Enacts Bill to Amend PMD Act
May 15, 2025
-
REGULATORY LDP Group Proposes Higher Cap on Social Security Budgets, Category-Based Drug Pricing
May 14, 2025
-
ACADEMIA Japan Consortium to Promote Domestic R&D of Cannabis-Derived Meds
May 14, 2025
ページ
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…